Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Sold by GSA Capital Partners LLP

GSA Capital Partners LLP lowered its position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) by 84.3% in the third quarter, HoldingsChannel.com reports. The fund owned 15,407 shares of the company’s stock after selling 82,997 shares during the quarter. GSA Capital Partners LLP’s holdings in Relay Therapeutics were worth $109,000 as of its most recent filing with the SEC.

Other large investors have also added to or reduced their stakes in the company. EverSource Wealth Advisors LLC acquired a new stake in shares of Relay Therapeutics during the second quarter worth about $37,000. Values First Advisors Inc. acquired a new position in Relay Therapeutics in the 3rd quarter worth approximately $75,000. Virtu Financial LLC purchased a new position in Relay Therapeutics during the 1st quarter worth approximately $87,000. China Universal Asset Management Co. Ltd. lifted its stake in Relay Therapeutics by 65.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 25,751 shares of the company’s stock valued at $182,000 after acquiring an additional 10,157 shares during the period. Finally, ProShare Advisors LLC boosted its holdings in shares of Relay Therapeutics by 14.9% in the 1st quarter. ProShare Advisors LLC now owns 26,214 shares of the company’s stock valued at $218,000 after acquiring an additional 3,394 shares during the last quarter. Hedge funds and other institutional investors own 96.98% of the company’s stock.

Relay Therapeutics Trading Up 2.3 %

Shares of RLAY opened at $4.86 on Tuesday. The firm has a market cap of $813.47 million, a P/E ratio of -1.86 and a beta of 1.67. Relay Therapeutics, Inc. has a 12 month low of $4.48 and a 12 month high of $12.14. The stock’s 50 day moving average is $6.29 and its two-hundred day moving average is $6.91.

Relay Therapeutics (NASDAQ:RLAY) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.14. The business’s revenue for the quarter was down 100.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.54) earnings per share. Equities research analysts forecast that Relay Therapeutics, Inc. will post -2.61 EPS for the current year.

Insider Buying and Selling at Relay Therapeutics

In other Relay Therapeutics news, CFO Thomas Catinazzo sold 6,802 shares of the stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $6.06, for a total transaction of $41,220.12. Following the completion of the transaction, the chief financial officer now owns 306,391 shares of the company’s stock, valued at $1,856,729.46. This represents a 2.17 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on RLAY. Jefferies Financial Group raised shares of Relay Therapeutics from a “hold” rating to a “buy” rating and raised their target price for the stock from $10.60 to $16.00 in a report on Tuesday, September 10th. Stifel Nicolaus reiterated a “buy” rating and set a $28.00 price objective on shares of Relay Therapeutics in a research note on Monday, September 16th. Barclays upped their target price on Relay Therapeutics from $14.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 10th. The Goldman Sachs Group started coverage on Relay Therapeutics in a research report on Tuesday, September 10th. They set a “buy” rating and a $20.00 price target for the company. Finally, HC Wainwright upped their price objective on Relay Therapeutics from $19.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $21.22.

Relay Therapeutics Profile

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.